Granules India has reported that USFDA has issued an Establishment Inspection Report (EIR) for Granules Pharmaceuticals Inc facility in Chantilly, USA. This facility was inspected by USFDA in December 2017 and had issued one Form 483 observation. The company has said that it responded to the observation within stipulated timeframe.This facility is recently established by Granules in the US and has spent ~Rs220cr in capex. This is a 100,000-sq foot facility and has R&D and formulation capabilities. Company expects to start manufacturing from this site. Company expected to increase the investment at this site going ahead.
CapitalStars Award Winning , SEBI registered , ISO certified investment advisory company. We provide intraday & positional services in Equity , derivative ,commodity & currency. Our research is highly skilled & experienced .
Investment & Trading in securities market is always subjected to market risks, past performance is not a guarantee of future performance.CapitalStars Investment Adviser: SEBI Registration Number: INA000001647
No comments:
Post a Comment